In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Boston Scientific returns Prochymal cardio rights to Osiris

Executive Summary

Boston Scientific and Osiris Therapeutics (connective tissue regeneration) are collaborating to develop a gene therapy for cardiovascular disease based on Osiris's mesenchymal stem cell (MSC) technology and combined with BS's injection catheter.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Medical Devices
    • Surgical Equipment & Devices
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • R+D and Marketing-Licensing
    • Includes Equity

Related Companies

Advertisement
UsernamePublicRestriction

Register